BIRC2 and neoplasm: These observations were corroborated in xenograft-bearing mice implanted with MDA-MB-231, in which tumor regression was achieved and molecular analyses confirmed the degradation of cIAP1 this compound is being considered as a candidate for clinical trials [47].